Active Ingredient History
Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized. On October 25, 2011, Eli Lilly & Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Sepsis (approved 2001)
Hematologic Neoplasms (Phase 4)
Hematopoietic Stem Cell Transplantation (Phase 4)
Hypotension (Phase 3)
Infections (Phase 4)
Kidney Failure, Chronic (Phase 2)
Pancreatitis (Phase 4)
Pre-Eclampsia (Phase 2)
Protein C Deficiency (Phase 2/Phase 3)
Pulmonary Embolism (Phase 2)
Respiratory Distress Syndrome (Phase 2)
Sepsis (Phase 4)
Shock, Septic (Phase 4)
Stroke (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue